Search

IRX-5183

Basic Fibroblast Growth Factor

Although it is not approved for use in Canada or the USA, bFGF is currently undergoing investigation in a number of clinical trials. … Basic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis.

Fluvoxamine

It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. … Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.

E5531

E5531 is an endotoxin antagonist.

Diacerein

It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea [L780]. … Diacerein is a prodrug which is metabolized to rhein.

PBI-1402

Since it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia. … PBI-1402 is a small molecule synthetic compound with oral Bioavailability.

4'-Methylene-5,8,10-trideazaaminopterin

CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier … (RFC) system than is Methotrexate.

Levobupivacaine

Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. … It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal

WX-UK1

WX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs. … Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas.

Nateglinide

Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. … One minor metabolite, the isoprene, has the same potency as its parent compound.